Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of ...

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

Researchers at the University of Iowa are part of a project designed to enhance treatment options for a common form of liver ...

University of Iowa researchers have been awarded federal funding to help develop an effective drug combination to treat a ...

The first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TUNE-401 in adult participants with chronic HBV. The initial clinical trial site ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

HCC risk prediction may be poorly reported and biased for individuals with nonviral chronic liver disease.

The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups, according to a new study. The ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.

“2024中华医学会肝病学分会学术年会”于2024年10月25-27日在厦门市召开。作为肝病领域水平极高的学术盛会，国内外著名专家学者及领域同行积极踊跃地参会，就病毒性肝炎、脂肪性肝病、肝纤维化、药物性肝病、自身免疫性肝病等肝脏疾病各方面的临床与基础 ...